OneSource Q4FY26 results show a sharp reset in earnings momentum

OneSource Specialty Pharma ended FY26 with a strong fourth quarter that changed the tone of the year. Consolidated revenue rose to ₹4,282 million in Q4FY26, up 47 percent quarter-on-quarter, as commercialisation picked up across the platform and India semaglutide launches added volume. Profitability moved even faster. EBITDA jumped to ₹919 million, more than five times the prior quarter, taking margin to 21 percent from 6 percent in Q3FY26. Adjusted PAT turned positive at ₹390 million, reversing the adjusted loss of ₹472 million in the previous quarter.

The full year still reads like a transition year. FY26 revenue was ₹14,216 million, down 2 percent year-on-year, while EBITDA fell 35 percent to ₹3,042 million and margin contracted to 21 percent from 32 percent in FY25. Management linked the softer second half to delayed semaglutide approvals in Canada, a high base of MSA revenue in the prior year, and an elevated cost base as the drug-device combination facility ramped up. The company also noted that the impact of the new labour code has been fully provided in FY26 financials.

What stands out is the direction of travel into FY27. Q4 showed operating leverage returning as higher CSA revenue flowed through the P and L, and the commercial engine broadened beyond one product cycle. CEO and MD Neeraj Sharma described the quarter as a broad-based recovery, citing successful semaglutide launches in India across multiple customer brands, alongside new launches in the US injectables and soft gelatin businesses. He also pointed to back-to-back semaglutide approvals in Canada and continued expansion of the biologics pipeline as supports for momentum.

Q4 recovery was powered by commercial launches and operating leverage

The sequential uplift in Q4 was not limited to one line item. Revenue growth was described as coming from all service offerings, with semaglutide commercialisation in India providing a clear catalyst. The mix mattered too. OneSource said margins expanded on operating leverage from higher CSA revenues during the quarter, which helped convert revenue into a much higher EBITDA run rate.

Adjusted earnings improved sharply, but it is important to read the bridge correctly. The company’s adjusted metrics exclude exceptional items and scheme-related intangible amortisation. For Q4FY26, the note in the press release cites exceptional items of ₹10.3 million and scheme-related intangible amortisation of ₹344 million. On a reported basis, PAT in Q4FY26 was ₹46 million, while adjusted PAT was ₹390 million.

The Q4 outcome also helps contextualise the FY26 decline. In the full year, reported PAT was negative at ₹738 million, while adjusted PAT was positive at ₹739 million. This gap is again driven by exceptional items and scheme-related intangible amortisation, which the company quantified for the year.

Financial summary

Semaglutide is the near-term volume engine, and the customer map is widening

OneSource’s FY26 narrative is closely tied to GLP-1 drug-device combinations, where it positions itself as a first mover among CDMOs. The company highlighted that it has been the CDMO partner for the first three generic semaglutide approvals in G7 countries, with two approvals in Canada and one in the US, alongside day-1 India launches through multiple partners.

The multi-market customer map matters because semaglutide is not a single geography story. In its market view, OneSource listed the top off-patent semaglutide markets by size using IQVIA 2025 sales and units. It also showed customer presence across Canada, Brazil, LatAm excluding Brazil, select rest-of-world markets, Saudi Arabia, Turkey, and India. In India, it noted multiple top-tier partners collectively commanding about two-thirds of the generic injectable semaglutide market based on April 2026 market share data.

Operationally, the company described its drug-device combination momentum through scale indicators. It cited three G7 semaglutide approvals, three GLP-1 molecules, eleven device platforms, and more than fifty drug-device combination projects. The semaglutide status grid in the presentation sets out where the launches are happening: India launched, Canada launching with partners Dr. Reddy’s and Orbicular, MENA launching with Hikma, and the US launch planned on patent expiry with partner Orbicular after USFDA approval.

The GLP-1 roadmap extends beyond semaglutide. Management noted that multiple customers completed NCE-1 filings for tirzepatide. Liraglutide was commercially launched during the year with one partner, with more launches scheduled in FY27.

Capacity expansion and compliance discipline are being treated as the backbone of FY27 execution

The bridge from a strong quarter to durable growth usually runs through capacity and regulatory readiness, especially in complex modalities. OneSource’s flagship site is in the middle of a cartridge capacity expansion. It reported about $80 million committed so far against a total announced capex of$100 million and said it added over 380 hires during FY26 to support the ramp-up. The second line at the flagship site is under qualification with commercial readiness targeted by Q2FY27. Two additional lines are planned under the ongoing capex programme, targeted for commissioning by FY27 in line with its medium-term capacity build-out roadmap.

Alongside capacity, the quality and compliance track record remains a core part of the company’s operating pitch. OneSource reported more than 210 successful audits and a 100 percent GMP inspection success rate. In FY26, it completed 49 successful regulatory inspections and customer audits with zero critical observations across all sites. It also highlighted specific milestones: an EIR received for the flagship site following a March 2025 inspection, EU GMP renewal for the SPD and flagship site, and ANVISA approval secured for the flagship site, which supports potential commercial supply into Brazil.

These compliance markers tie directly to the commercial pipeline. As launches expand across geographies, the ability to pass regulator and customer scrutiny without disruption becomes a growth enabler, not just a hygiene factor.

Beyond GLP-1, biologics, injectables, and softgels are positioned as the next layers of scale

OneSource is building a pure-play CDMO platform across four offerings: drug-device combinations, biologics, soft gelatin capsules, and sterile fill-finish. FY26 business updates suggest that the company is trying to avoid a single-product dependence by widening both modalities and customer relationships.

In biologics, the company called the segment an emerging next growth engine with strong industry tailwinds. It reported a four times increase in the biologics funnel during FY26 and noted it signed a second project with a top three global animal health company. It also pointed to being one of the few integrated drug substance and drug product sites globally, with installed microbial capacity of 1 KL and installed mammalian capacity of 4 KL, plus a 20 KL reactor available on site. It also mentioned planned addition of 5 KL microbial capacity. Strategically, the company said it is actively scouting a US or EU beachhead to be closer to innovators and early-stage biotech companies.

In injectables and softgels, the update was more commercial and deal-driven. During FY26, OneSource reported more than ten new licensing and CDMO deals and more than fifteen new commercial launches. It also stated it has more than thirty-five approved and on-market products in the US under its own IP. In softgels, it cited installed capacity of 2.4 billion capsules per year. In sterile injectables, it highlighted that EU GMP approval of the SPD plant enables a pathway for commercialisation in Europe, and it is expanding capabilities in long-acting injectables and lyophilisation.

The company also provided platform-level activity metrics for FY26: 31 new MSAs and licensing agreements signed, 18 injectable and softgel product launches, five new logos added taking total customers to more than 75, and more than 70 active REPs across modalities. It added that more than fifty customers are partners on two or more projects or products, a useful indicator of repeat business and cross-sell.

Acquisition pause removes near-term complexity, while FY28 targets remain the anchor

OneSource also addressed an important governance and capital allocation topic: the proposed acquisition of two USFDA-approved specialty injectable assets from Steriscience. The scheme of arrangement was announced in September 2025 and received an NOC from Indian stock exchanges on 26 February 2026. However, the company said some stakeholders raised concerns on valuation. The board approved not to pursue the transaction in the current form and to revisit it after successful delivery of both companies’ FY28 guidance.

For investors, this is a meaningful signal. The company is choosing to protect focus and execution in the near term rather than litigate valuation debates while it is scaling core capacities.

The anchor for that execution remains FY28 guidance, which management reaffirmed. OneSource reiterated its target of about $400 million in organic revenue and about 40 percent steady state EBITDA margin, with targeted ROCE above 50 percent. It framed the path as all businesses contributing, with operating leverage amplifying the financial impact as scale builds. The execution levers highlighted were GLP-1 scaling across markets supported by capacity expansion, an expanding biologics funnel with continued pipeline growth and MSA execution, and enhanced sterile injectable and softgel platforms through capability expansion.

What to watch after Q4FY26

Q4FY26 does not erase the fact that FY26 was a softer year on profit and margins. But it does provide evidence that the business can swing back quickly when commercialisation aligns with capacity and mix. The quarter’s sharp margin recovery suggests that a meaningful part of the FY26 pressure was timing and ramp-related rather than structural.

The next phase will test whether that recovery can hold as volumes rise. The qualification and readiness of the second line at the flagship site by Q2FY27 will be a key operational milestone. Progress on semaglutide launches in Canada and the MENA region, and the pace of additional GLP-1 programs such as liraglutide and tirzepatide filings, will shape revenue cadence. Parallelly, the ability to convert the expanding biologics funnel into signed MSAs and executed projects will indicate whether the platform can broaden beyond GLP-1.

The company’s message at the end of FY26 is consistent: a transition year is giving way to an execution year. With FY28 guidance reaffirmed and a visible capacity build-out underway, OneSource is positioning FY27 as the period where commercial scale and operating leverage start to look more like a trend than a quarter.